What are the management and monitoring recommendations for a patient taking Farxiga (dapagliflozin) for diabetes?

Management and Monitoring Recommendations for Patients Taking Farxiga (Dapagliflozin)

Patients taking Farxiga (dapagliflozin) should be monitored annually for kidney function through eGFR and urinary albumin:creatinine ratio assessment, and should be educated about potential side effects including genital mycotic infections, urinary tract infections, and diabetic ketoacidosis.

Dosing and Renal Function Considerations

Dosing Recommendations

• Initial dosing: 5 mg orally once daily for glycemic control
• Can be increased to 10 mg once daily for additional glycemic control
• For cardiovascular and kidney protection: 10 mg once daily 1

Renal Function Monitoring

• Assess renal function prior to initiation and periodically thereafter 1
• Not recommended for glycemic control in patients with eGFR <45 mL/min/1.73m² 1, 2
• Can be used for cardiovascular and kidney protection with eGFR as low as 20-30 mL/min/1.73m² 3, 4
• Discontinue when dialysis is initiated (though limited evidence suggests dapagliflozin may be safe in dialysis patients) 4

Cardiovascular and Renal Benefits

• Dapagliflozin reduces risk of:

  • Cardiovascular death and hospitalization for heart failure 1
  • Sustained eGFR decline and kidney failure 2, 3
  • Progression of diabetic kidney disease 5, 6

• Consider dapagliflozin as first-line agent for kidney and heart protection for those with:

  • eGFR ≥20 mL/min/1.73m² and
  • Urinary albumin:creatinine ratio ≥200 mg/g 4

Monitoring for Adverse Effects

Regular Monitoring

• Annual screening for kidney disease (eGFR and urinary albumin:creatinine ratio) 3
• Monitor for signs of:
  • Volume depletion (especially in elderly or those on diuretics) 1
  • Urinary tract infections and genital mycotic infections 1, 7
  • Diabetic ketoacidosis, even with normal blood glucose levels 1, 8

Specific Side Effects to Monitor

1. Genital Mycotic Infections

   • Most common adverse effect, particularly in women 9, 7
   • Educate patients on genital hygiene to mitigate risk 4

2. Urinary Tract Infections

   • Slightly increased risk compared to placebo 7
   • Generally mild to moderate and respond to standard antimicrobial treatment 7

3. Diabetic Ketoacidosis (DKA)

   • Rare but serious; can occur with normal blood glucose levels (euglycemic DKA) 1, 8
   • Higher risk during acute illness or fasting 8

4. Volume Depletion

   • Monitor for symptoms of hypotension, especially in elderly patients or those on diuretics 1

Sick Day Management

When to Temporarily Discontinue Farxiga

• During acute illness with nausea, vomiting, or diarrhea 8, 4, 10
• Before scheduled surgery (3-4 days prior) 8
• During critical illness or prolonged fasting 8
• When experiencing significant abdominal pain 10

Patient Instructions for Sick Days

• Stop taking Farxiga immediately if experiencing significant symptoms 10
• Maintain adequate hydration 10
• Seek urgent medical evaluation if unable to maintain fluid intake 10
• Monitor for ketones if available 8
• Resume medication after resolution of acute illness 10

Drug Interactions and Combination Therapy

• Consider reducing doses of insulin or insulin secretagogues when used with Farxiga to reduce hypoglycemia risk 1
• Farxiga can be used in combination with other antidiabetic medications due to its complementary mechanism of action 9, 11
• Farxiga may facilitate use of other guideline-directed therapies (RAS inhibitors, mineralocorticoid receptor antagonists) by reducing hyperkalemia risk 4

Patient Education

• Provide education on:
  • Genital hygiene to prevent infections 4
  • Sick day management protocol 8, 4
  • Recognition of DKA symptoms, even with normal glucose levels 8
  • Importance of adequate hydration 10
  • Self-monitoring for signs of urinary tract infections 1

Special Considerations

• Expect a reversible decline in eGFR of 3-5 mL/min/1.73m² in first 4 weeks of therapy (eGFR dip) 4
• Monitor renal function within one week after restarting medication following illness 10
• Assess volume status before initiating, particularly in elderly patients or those on diuretics 1

By following these comprehensive management and monitoring recommendations, healthcare providers can maximize the benefits of Farxiga while minimizing potential risks for patients with diabetes.